Hair Loss Biotechs Emerge As Wall Street's Newest Growth Trade
Hair loss biotechs are racing to deliver the first new baldness treatments in nearly three decades, and investors are positioning for the payoff. Veradermics, Absci, and Cosmo Pharmaceuticals are advancing a pill, an injection, and a topical drug for pattern hair loss, a condition with no newly approved therapy since the late 1990s. Hair Loss Biotechs Eye A Market Waiting For A Cure Pattern hair loss affects an estimated 50 million men and 30 million women in the United States, according to Bloomberg. Current options are limited to decades-old drugs minoxidil and finasteride. Both are tied to side effects that include heart palpitations and reduced sex drive. Sponsored Sponsored Veradermics (NYSE: MANE) is developing an oral pill, VDPHL01, and its stock has climbed nearly 500% since its February IPO. Absci (NASDAQ: ABSI) is testing an injection dosed two to three times over six months, and its shares have more than doubled so far this year. Cosmo Pharmaceuticals posted positive late-stage trial results for a topical solution but has traded more cautiously against its US rivals. Investors Chase A GLP-1 Style Trade The enthusiasm echoes Eli Lillys stock rally, which reshaped investor appetite for consumer health biotech. Its weight loss drugs first drove that shift. Eli Lillys stock is up nearly
